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Advanced age and DNA damage accumulation are
prominent risk factors for cancer. The premature ag-
ing disorder Hutchinson-Gilford progeria syndrome
(HGPS) provides a unique opportunity for studying
the interplay between DNA damage and aging-asso-
ciated tumor mechanisms, given that HGPS patients
do not develop tumors despite elevated levels of
DNA damage. Here, we have usedHGPSpatient cells
to identify a protective mechanism to oncogenesis.
We find that HGPS cells are resistant to neoplastic
transformation. Resistance is mediated by the bro-
modomain protein BRD4, which exhibits altered
genome-wide binding patterns in transformation-
resistant cells, leading to inhibition of oncogenic
dedifferentiation. BRD4 also inhibits, albeit to a lower
extent, the tumorigenic potential of transformed cells
from healthy individuals. BRD4-mediated tumor pro-
tection is clinically relevant given that a BRD4 gene
signature predicts positive clinical outcome in breast
and lung cancer. Our results demonstrate a protec-
tive function for BRD4 and suggest tissue-specific
roles for BRD4 in tumorigenesis.
INTRODUCTION
Neoplastic transformation is a multistep process whereby
normal cells acquire a distinct set of cellular properties and
develop into malignant derivatives (Hanahan and Weinberg,
2000). Transformation often involves an oncogenic reprogram-
ming process during which cells dedifferentiate and take on
functional properties of tumor-initiating cells (Scaffidi and Mis-
teli, 2011; Schwitalla et al., 2013; Vicente-Duen˜as et al., 2013).
Common triggers for oncogenic transformation include intrinsic
and extrinsic insults such as replication stress, irradiation, and248 Cell Reports 9, 248–260, October 9, 2014 ª2014 The Authorsexposure to environmental chemicals, all of which lead to
genetic and epigenetic alterations (Hanahan and Weinberg,
2000). A prominent cause of oncogenic transformation is the
accumulation of DNA damage as indicated by the markedly
increased susceptibility to cancer in diseases caused by muta-
tions in the DNA repair machinery (Hoeijmakers, 2009; Venkitara-
man, 2002). Interestingly, several of these diseases, such as
Werner syndrome and Bloom syndrome, manifest themselves
as premature aging disorders (Brosh and Bohr, 2007), high-
lighting the complex relationship among DNA damage, cancer,
and aging.
A striking example of a premature aging disease characterized
by dramatically elevated levels of DNA damage is Hutchinson-
Gilford progeria syndrome (HGPS). HGPS is caused by a muta-
tion in the LMNA gene, which encodes lamin A and lamin C, two
major architectural components of the cell nucleus (De Sandre-
Giovannoli et al., 2003; Eriksson et al., 2003; Scaffidi et al., 2005).
The HGPSmutation leads to the accumulation of an alternatively
spliced variant of lamin A, named progerin, which acts in a
dominant gain-of-function fashion and induces nuclear defects,
including chromatin changes and high levels of constitutive DNA
damage (Scaffidi et al., 2005; Scaffidi andMisteli, 2006). Patients
with HGPS display numerous symptoms of accelerated and
normal aging, including cardiovascular defects, bone abnormal-
ities, and lipodystrophy, and the disease is invariably fatal (Gor-
don et al., 2014). Low levels of progerin are also expressed in
healthy individuals and induce age-related nuclear abnormalities
similar to those observed in HGPS, suggesting relevance of
HGPS to the normal aging process (Cao et al., 2007; McClintock
et al., 2007; Scaffidi and Misteli, 2006). Remarkably, despite
exceedingly high levels of DNA damage, HGPS patients do not
develop cancers (Gordon et al., 2014).
In this study, we sought to identify the molecular basis for the
observed resistance to cancer in HGPS. We find that patients
with HGPS are protected from cancer by a cell-intrinsic mecha-
nism, which inhibits neoplastic transformation and dedifferen-
tiation of HGPS cells toward a malignant stem-cell-like state.
Using a functional genomics approach, we identify the general
transcriptional regulator BRD4 as a key mediator of resistance
to transformation. We show that BRD4 is redistributed on chro-
matin in transformation-resistant cells and activates tumor-pro-
tective cellular pathways. Importantly, BRD4 also protects cells
from healthy individuals, and we provide evidence for clinical
relevance of this mechanisms in breast and lung cancer.
RESULTS
HGPS Fibroblasts Are Resistant to Experimental
Transformation
We hypothesized that the observed absence of tumors in HGPS
patients, despite high loads of cellular DNAdamage (Figure S1A),
is caused by the presence of intrinsic tumor resistance mecha-
nisms in HGPS cells rather than the limited lifespan of HGPS
patients. To directly test this hypothesis, we experimentally as-
sessed the transformation potential of HGPS patient cells. Pri-
mary skin fibroblasts from multiple patients with HGPS and
age-matched control wild-type individuals were challenged in
a standard transformation assay by retroviral introduction of
TERT (T), V12-HRAS (R), and SV40 large and small T antigens
(S) (Hahn et al., 1999). Both wild-type and HGPS cells expressing
the transforming factors (referred to as TRS-WT and TRS-HGPS,
respectively) underwent morphological changes typically ob-
served upon transformation (Figure S1B), proliferated at com-
parable rates, and, as expected, faster than control cells
expressing telomerase only (Figure S1C). When tested in soft
agar assays, TRS-HGPS cells showed reduced clonogenic
capacity compared to TRS-WT cells. Whereas TRS-WT cells
efficiently formed colonies at a frequency of 1:2–1:5, the colony
formation frequency of TRS-HGPS was only 1:33–1:108 (p <
0.01; Figures 1A and 1B). The reduced clonogenic capacity of
TRS-HGPS was not due to differences in proliferation rates or
levels of TERT, SV40 T-antigens, or HRASmRNA or protein (Fig-
ures S1C–S1E). Resistance of HGPS cells to transformation was
confirmed in vivo by transplantation of TRS cells into nude mice
(Figures 1C and 1D).Whereas 11 of 16 injections of TRS-WT cells
induced tumors, only 1 of 16 injections of TRS-HGPS cells from
two different patients generated a small tumor that appeared
3–4 weeks later than the wild-type tumors and grew more slowly
(p < 0.01, Figures 1C and 1D). Differences in tumorigenicity were
orroborated in immunocompromised NSG mice, excluding
the possibility of host effects (TRS-WT: 16/16 outgrowths,
TRS-HGPS 0/8; Figure S1F).
Transformation resistance of HGPS cells was supported by
global gene expression analysis. Although expression of 786
genes changedmore than 2-fold during transformation of control
wild-type cells, only 15%of those responded to the transforming
factors in HGPS cells (Figures 1E and 1F). In contrast to TRS-WT
cells, TRS-HGPS cells failed to activate several oncogenic path-
ways including RAS, vascular endothelial growth factor (VEGF),
ERB2, epidermal growth factor receptor (EGFR), and gene sig-
natures of cytokine and chemokine activities (Figure S2), as
determined by gene set enrichment analysis (GSEA). On the
other hand, TRS-HGPS cells failed to downregulate fibroblast-
related pathways during the transformation process, such as
those involved in extracellular matrix organization (p < 1013),
collagen fibril organization (p < 109), and skin development(p < 108; Figure S2D). Whereas several collagens and other
extracellular matrix components, which are highly expressed
by fibroblasts, showed up to 80% downregulation in TSR-WT
cells compared to untransformed cells, no significant reduction
was seen in TRS-HGPS cells (Figure 1G), indicating that, unlike
wild-type cells, HGPS cells retain their fibroblast identity upon
experimental transformation. Moreover, gene signatures associ-
atedwith human stem cells, such asmammary (Pece et al., 2010)
and mesenchymal stem cells (Secco et al., 2009), were enriched
in tumorigenic TRS-WT cells, but not in transformation-resistant
TRS-HGPS cells (Figures 1H and S2B; see below). Whereas
TRS-WT cells were able to efficiently differentiate into adipo-
cytes in vitro, TRS-HGPS failed to do so, further confirming their
inability to reprogram (Figure S2E). We conclude that HGPS cells
are refractory to oncogenic challenges and fail to undergo effi-
cient de differentiation and neoplastic reprogramming required
for acquisition of tumor-initiating ability (Scaffidi and Misteli,
2011; Schwitalla et al., 2013).
Progerin Is Necessary and Sufficient for
Tumor Protection
The observed transformation resistance of HGPS cells may be
due to the action of progerin or may be a secondary, adaptive
response of HGPS cells. To distinguish between these possi-
bilities, we performed knockdown and overexpression experi-
ments. Silencing of progerin in TRS-HGPS cells (Figure S3A)
resulted in a 6-fold increase in the number of colonies formed
in soft agar compared to control cells expressing shGFP (p <
0.01; Figure 2A) and restored the ability to form tumors in vivo
(three of three; Figure 2B), demonstrating that progerin is
required for tumor protection. Conversely, induction of ectopic
expression of progerin in TRS-WT cells induced a 2-fold reduc-
tion in the number of colonies in vitro (Figure 2C, p < 0.01) and
completely suppressed their ability to form tumors in nude
mice (zero of five; Figure 2D). As a control, expression of wild-
type lamin A did not impair tumor formation (four of five; Fig-
ure 2D). These results indicate that progerin is both necessary
and sufficient to protect from oncogenic transformation. Further-
more, they show that the progerin-dependent protective mech-
anism can be reactivated in already transformed cells.
Identification of BRD4 as a Mediator of
Transformation Resistance
To identify factors that mediate transformation resistance,
we performed an RNAi-based loss-of-function screen. TRS-
HGPS cells were transduced with a pooled genome-wide
shRNA library and cells were grown in soft agar for 4 weeks
(see Experimental Procedures). shRNAs restoring clonogenic
capacity in TRS-HGPS cells were recovered from colonies
and identified by hybridization on microarrays (Figure 3A).
Three independent screens were performed and 167 hits
showing enrichment over the control population (transduced
cells grown for 3 days as monolayer) in all three experiments
were identified (Table S1). We focused on DNA-binding pro-
teins and transcription regulators because they represented
the most prominent class of proteins based on GO analysis
(p < 0.003; Figure 3B) and because chromatin defects have
been strongly implicated in HGPS (Scaffidi et al., 2005).Cell Reports 9, 248–260, October 9, 2014 ª2014 The Authors 249
Figure 1. HGPS Fibroblasts Are Resistant to Experimental Transformation
(A and B) Soft agar assay using transformed fibroblasts from two HGPS patients (TRS-HGPS1 and TRS-HGPS2) and aged-matched wild-type individuals
(TRS-WT1 and TRS-WT2). Representative images ofMTT-stained colonies (A) and quantification of colony formation (B) are shown. Values representmean ± SEM
(n = 3). Statistical significance is indicated by one asterisk (p < 0.01, TRS-HGPS cell lines versus TRS-WT2 cell line, one-way ANOVA followed by Dunnett’s test).
(C and D) In vivo transplantation assays into nude mice (2.5 million injected cells). Image of a representative mouse in which TRS-WT (left flank) and TRS-HGPS
(right flank) cells were injected (C) and quantification of tumor growth (D). Values of tumor volume represent mean ± SEM from eight injections for each cell line.
Statistical significance is indicated by one asterisk (p = 0.0044, Student’s t test).
(E) Heatmap representing relative expression of differentially expressed genes (DEG, fold R 2, p < 0.05) in TRS-WT cells compared to TRS-HGPS cells;
expression of these genes is shown for all cell lines before and after experimental transformation. Red and blue represent the highest and lowest values of each
gene among all samples, respectively.
(F) Venn diagram showing number of DEG during transformation in WT cells and HGPS cells (TRS-cells compared to TERT-cells).
(G) Relative expression of fibroblast-related genes in TRS-WT and TRS-HGPS cells compared to expression in their corresponding TERT-cell lines (dashed line).
Average values frommultiple probe sets from RMA normalized microarray data were determined for each gene. Values represent mean ± SEM from two cell lines
in each group.
(H) GSEA of indicated signatures on TRS-HGPS versus TRS-WT cells. NES, normalized enrichment score; FDR q-val, false discovery rate q- value.Sixteen of 58 selected candidates were confirmed in vitro by
soft agar assays (Figure 3C and Table S2) and three of seven
of the top hits were positive in transplantation assays in NSG
mice (Figure 3D).
The hit showing the strongest effect in vivo was the bromodo-
main-containing 4 protein (BRD4). BRD4 is a member of the BET
family of bromodomain-containing proteins that binds acety-
lated histones and modulates gene expression by recruiting
transcriptional regulators to specific genomic locations (Wu250 Cell Reports 9, 248–260, October 9, 2014 ª2014 The Authorsand Chiang, 2007). BRD4 has been implicated in cellular growth,
gene bookmarking, and postmitotic transcription (Dey et al.,
2003, 2009; Mochizuki et al., 2008; Zhao et al., 2011). BRD4
has a strong cancer-promoting role in hematopoietic malig-
nancies (Dawson et al., 2011; Delmore et al., 2011; Mertz
et al., 2011; Ott et al., 2012; Zuber et al., 2011) and has been
implicated in breast cancer as an antimetastatic protein and in
colon cancer as an antiproliferative factor (Alsarraj et al., 2011;
Crawford et al., 2008; Rodriguez et al., 2012). Reduction of
Figure 2. Progerin Suppresses Tumorige-
nicity of Transformed Fibroblasts
(A) Soft agar assay using TRS-HGPS cells in which
progerin has been stably knocked down. TRS-
HGPS cells expressing shRNAs against LMNA
(shLMNA) or GFP (shCtrl) were used as controls.
Values represent mean ± SEM (n = 4–6). Statistical
significance is indicated by one or two asterisks
(p < 0.05, p < 0.01, respectively, one-way ANOVA
followed by Dunnett’s test).
(B) In vivo transplantation assays into NSG mice
using TRS- HGPS cells in which progerin has been
stably knocked down (2.5 million injected cells).
Values of tumor volume represent mean ± SEM
from 3–4 injections for each cell line. Statistical
significance is indicated by one asterisk (p < 0.01,
two-way ANOVA followed by Bonferroni posttest).
(C) Soft agar assay using TRS-WT cells expressing
GFP-wild-type lamin A (TRS-WT-GFP-wtLaminA)
or GFP-progerin (TRS-WT-GFP-progerin). The
number of colonies formed by each induced cell
line (On) is normalized to their respective non-
induced cell lines (Off). Values represent mean ±
SEM (n = 4). Statistical significance is indicated by
two asterisks (p < 0.001, Student’s t test). Repre-
sentative images of colonies growing with or
without induction of GFP-wtLamin A or GFP-pro-
gerin are shown.
(D) In vivo transplantation assays into nude mice
using induced cell lines expressing GFP-lamin A or
GFP-progerin (2.5 million injected cells). Values of
tumor volume represent mean ± SEM from five
injections for each cell line. Statistical significance
is indicated by one asterisk (p < 0.01, two-way
ANOVA followed by Bonferroni posttest).BRD4 by 60% using multiple shRNAs in TRS-HGPS cells
increased colony formation 4- to 5-fold (Figures 3E and S3C)
and promoted efficient tumor formation (four of four tumors for
shBRD4-1; three of three for shBRD4-3; Figures 3D and 3F).
Given the reported role of BRD4 in promoting hematological
cancers, we also assessed the tumorigenic potential of trans-
formed B-lymphocytes from patients with HGPS and age-
matched healthy individuals. As expected, due to the very low
expression levels of lamin A, and thus progerin, in lymphocytes
(Gerner and Sauermann, 1999; Ro¨ber et al., 1990; Figures
S3G, S3H, and S3J), transformed HGPS B-lymphocytes did
not display typical progerin-induced nuclear defects (Figures
S3G and S3I) and formed colonies at similar frequency as wild-
type controls (p > 0.05; Figure S3K).
Genome-wide Redistribution of BRD4 in
Transformation-Resistant Cells
An obvious potential mechanism for the protective effect of
BRD4 is its upregulation in HGPS cells. This was not the case,
given that BRD4 levels were similar in TRS-HGPS cells
compared to TRS-WT cells (Figures S3D–S3F). Strikingly, how-
ever, genome-wide mapping by chromatin immunoprecipitation
sequencing (ChIP-seq) in multiple cell lines showed differential
genome binding patterns of BRD4 in TRS-WT compared to
TRS-HGPS cells (Figure 4; Figures S4A and S4B). In agreement
with the notion that BRD4 regulates transcription by binding toboth gene promoters and intergenic enhancers (Love´n et al.,
2013), 9% (350 sites) and 43% (1,621 sites) of shared
BRD4 binding sites between TRS-WT and TRS-HGPS cells
localized at promoters or intergenic regions, respectively (Fig-
ure 4B). TRS-WT-specific BRD4 binding sites showed a similar
genomic distribution (11% at promoters, 34% at intergenic
regions). In contrast, only 1% of TRS-HGPS-specific binding
sites were in promoter regions, whereas 43% of the binding
sites were intergenic, indicating genomic redistribution of
BRD4 (Figures 4A–4C). Among BRD4 binding sites shared be-
tween TRS-WT and TRS-HGPS cells, over 300 regions showed
enhanced binding (R2-fold) in TRS-HGPS cells (Figure 4D), indi-
cating that redistribution of BRD4 entailed both binding to
distinct genomic sites and accumulation at locations occupied
at low levels in TRS-WT cells. Interestingly, numerous BRD4
binding sites are in proximity to genes that differentially respond
to transformation in TRS-HGPS and TRS-WT cells, including
several collagen genes, FN1, and metallopeptidases (Figure 1G;
Table S3). Knockdown of progerin in TRS-HGPS cells restored
TRS-WT-like BRD4 binding patterns (Figure 4E). We conclude
that BRD4 exhibits altered binding patterns in TRS-HGPS cells,
as a result of both redistribution onto distinct genomic regions
and accumulation at sites bound at lower levels in TRS-WT cells.
In line with its genome-wide redistribution, BRD4 exhibited
distinct cellular behavior in TRS-WT compared to TRS-HGPS
cells. Although BRD4 was distributed throughout the nucleusCell Reports 9, 248–260, October 9, 2014 ª2014 The Authors 251
(legend on next page)
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Figure 4. Distinct Genomic Distribution of BRD4 Binding Events in TRS-HGPS Cells
(A) Distribution of TRS-WT- and TRS-HGPS-specific binding sites around gene transcription start sites (TSS).
(B) Genomic distribution of the indicated sets of BRD4 binding sites. The percentage of sites in each genomic class is indicated.
(C and D) Tracks of BRD4 binding sites in the indicated genomic regions. TRS-WT-specific site in the promoter region ofHDAC1 (C, left) and TRS-HGPS-specific
sites in an intergenic region of chromosome 2 (C, right). Examples of BRD4 binding sites common to both TRS-WT and TRS- HGPS cells, but showing enhanced
binding (R2-fold) in TRS-HGPS cells (D).
(E) Differential BRD4 binding to genome regions by ChIP-qPCR. Percent age of input was normalized to H3ChIP-qPCR. Negative BRD4 binding was assessed by
NANOG TSS qPCR and mean value is represented by the dashed line. Bars represent mean ± SEM (n = 3–4). Statistical significance is indicated by one asterisk
(p < 0.05, Student’s t test, TRS-HGshProgerin versus TRS-HGPS).of TRS-WT cells, it accumulated in distinct foci in TRS-HGPS
cells together with acetylated histone H4 (H4Ac), a major binding
substrate (Figures 5A, 5B, and S5C). TRS-HGPS cells showedFigure 3. A Genome-wide shRNA Screen Identifies BRD4 as a Mediato
(A) Outline of the performed functional genome-wide shRNA screen.
(B) Gene ontology analysis of positive hits by DAVID. The top enriched cluster an
(C) Soft agar assay using TRS-HGPS cells in which selected hits have been stab
gene candidates, GFP (shCtrl) and progerin (shProgerin) were assessed for colo
(D) In vivo transplantation assays into NSGmice using TRS-HGPS cells in which t
down (2.5 million injected cells). Untransduced TRS-HGPS cells were used as co
Values of tumor volume represent mean ± SEM from four injections for each ce
ANOVA followed by Bonferroni posttest).
(E) Soft agar assay using TRS-HGPS cells in which BRD4 has been stably knocke
GFP (shCtrl) were assessed for colony formation. Values represent mean ± SEM (n
ANOVA followed by Dunnett’s test).
(F) In vivo transplantation assays into NSG mice using TRS-HGPS cells in which
injected cells). Untransduced TRS-HGPS cells were used as control cells. Values o
line. Statistical significance is indicated by two asterisks (p < 0.01, two-way ANOaltered histone modification patterns, displaying large accumu-
lations of H4Ac in regions of the nucleus but overall reduced
levels of the modification compared to TRS-WT cells (Figuresr of HGPS Cells Oncogenic Resistance
d individual p values corresponding to the specific GO terms are shown.
ly knocked down. TRS-HGPS cells expressing the indicated shRNAs against
ny formation. Values represent mean ± SEM (n = 4–6).
he indicated proteins (in vitro validated positive hits) have been stably knocked
ntrol. Values inside parentheses indicate number of outgrowths per injections.
ll line. Statistical significance is indicated by one asterisk (p < 0.05, two-way
d down. TRS-HGPS cells expressing the indicated shRNAs against BRD4 and
= 4–6). Statistical significance is indicated by two asterisks (p < 0.01, one-way
BRD4 has been stably knocked down using the indicated shRNA (two million
f tumor volume represent mean ±SEM from three to four injections for each cell
VA followed by Bonferroni posttest).
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Figure 5. Distinct HistoneModification Pat-
terns in TRS-HGPSCells Alter BRD4Subnu-
clear Distribution and Chromatin Binding
Dynamics
(A) Immunofluorescencemicroscopy on TRS-WT1
and TRS-HGPS1 cells. Cells were either immu-
nostained with an anti-BRD4 antibody (top) or an
anti-H4Ac antibody (bottom) or imagedas live cells
upon transduction with a construct expressing a
Cherry-BRD4 (Ch-BRD4) fusion protein (middle).
BRD4 accumulates in large nuclear foci in TRS-
HGPS cells. The graphs in green are line scans of
fluorescence intensity in the regionsmarked by the
red bars. Scale bar represents 5 mm.
(B) Immunofluorescence microscopy on a TRS-
HGPS1 cell expressing Ch-BRD4. Cells were
fixed and stained with an anti-H4Ac. Colocaliza-
tion of Ch-BRD4 foci and H4Ac foci is indicated by
arrows and analyzed by line scan of fluorescence
intensity (red bar).
(C) Distributions of the size of H4Ac foci in TRS-
WT1 and TRS-HGPS1 cells (n > 1000, p < 0.001,
Kolmogorov-Smirnov test). Foci with area greater
than 20 pixels were defined as large foci.
(D) Global H4-acetylation (H4Ac) was assessed by
western blot on purified histones from TRS-WT
and TRS-HGPS cell lines. Total H3 expression
level was used for normalization. A representative
immunoblot is shown. Relative densitometry
values are indicated.
(E) FRAP analysis (Half-FRAP, see Experimental
Procedures) of Ch-BRD4 in the indicated cell
lines. Quantitative analysis of recovery of the
fluorescence signal in the entire bleached area
(half nucleus). Values are averages from 10–14
cells. Similar results were obtained in three inde-
pendent experiments. For clarity, error bars are
omitted; typical SEs were below 10%. Statistical
significance is indicated by two asterisks (p <
0.01) and was estimated by trying to fit the
experimental points measured in the TRS-HGPS
cell lines using the best fit model of the experi-
mental points measured in TRS-WT1 cells (TRS-
HGPS1 reduced c2 = 11.6; TRS-WT1-progerin
reduced c2 = 145.5).
(F) FRAP analysis (Spot-FRAP, see Experimental Procedures) of Ch-BRD4 in living TRS-HGPS cells. Quantitative analysis of recovery of the fluorescence signal in
the bleached area (either a Ch-BRD4 focus or a nucleoplasmic region of identical size). Values are averages from at least five cells ± SE. Statistical significance is
indicated by two asterisks (p < 0.01) and was estimated by Student’s t test comparing the relative fluorescence values 4 s after bleaching.5A–5D and 4D). Similar differences were observed for acetylated
H3K9, anothermajor BRD4 binding substrate (Figure S4D). Alter-
ations in histone modification patterns in TRS-HGPS are in
agreement with observations in primary HGPS cells (McCord
et al., 2013; Pegoraro et al., 2009; Scaffidi and Misteli, 2005;
Shumaker et al., 2006) and confirm that the presence of progerin
leads to global chromatin changes. Using quantitative fluores-
cence recovery after photobleaching to measure chromatin
binding of BRD4 in living cells, Cherry-BRD4 had a significantly
slower recovery kinetics in TRS-HGPS cells, compared to
TRS-WT cells, indicating stronger binding to chromatin (p <
0.01; Figures 5E, 5F, and S4E). Slowed recovery indicative of
more persistent binding was particularly pronounced in H4Ac
foci (T50foci = 2.5 s, T50nucleoplasm = 9 s; Figure 5F). Binding of
BRD4 to chromatin was affected by progerin because induction254 Cell Reports 9, 248–260, October 9, 2014 ª2014 The Authorsof progerin in TRS-WT cells significantly reduced the mobility of
Cherry-BRD4 to levels measured in TSR-HGPS cells, demon-
strating that progerin affects BRD4 chromatin binding properties
(Figure 5E). We conclude that although there are not significant
differences in BRD4 expression level in HGPS cells, BRD4
genome distribution and binding properties are altered.
Identification of BRD4-Sensitive Genes Involved
in Transformation
To characterize cellular pathways involved in BRD4-mediated
tumor resistance, we performed gene expression analysis.
Consistent with the observed failure to activate various trans-
formation pathways, comparison of expression profiles of
TRS-HGPS-shBRD4 cells with those of TRS-WT and TRS-
HGPS cells confirmed reversal of the resistant phenotype in
Figure 6. BRD4 Protects from Dedifferentiation toward a Stem-Cell-like State during Transformation
(A) Heatmap representing relative expression of DEG in TRS-HGPS cells compared to TRS-WT cells, which respond to BRD4 knockdown.
(B) GSEA plots showing enrichment of indicated gene sets in TRS-HGPS-shBRD4 versus TRS-HGPS cells. NES, normalized enrichment score; FDR q-val, false
discovery rate q-value.
(C) Relative expression of fibroblast-relatedmarkers in TRS-WT and TRS-HGPS-shBRD4 cells compared to expression in TRS-HGPS-cells. Average values from
individual probe sets from RMA normalized microarray data were determined for each gene. Values represent mean ± SEM (n = 2–3).
(D) Sphere formation assay of indicated cell lines. Values represent mean ± SEM (n = 4–6). Statistical significance is indicated by two asterisks (p < 0.01, one-way
ANOVA followed by Dunnett’s t test).HGPS cells upon BRD4 silencing. Knockdown of BRD4 in TRS-
HGPS cells resulted in differential expression (fold change > 2,
false discovery rate [FDR] adjusted p < 0.05) of 256 genes, 43%
of which (111; 66 upregulated, 45 downregulated) overlapped
with genes differentially expressed between TRS-WT cells
and TRS-HGPS cells (Figure 6A). GSEA indicated that transfor-
mation-sensitive gene sets, defined as differentially expressed
in TRS-WT cells versus T-WT cells (Table S3), were reactivated
upon BRD4 knockdown (Figure S5B). Moreover, TRS-HGPS-
shBRD4 cells reexpressed oncogenic gene networks, including
the RAS signature, similarly to wild-type cells (Figures S5B
and S5C).
ChIP-seq analysis of BRD4 binding sites in TRS-WT and TRS-
HGPS cells had revealed numerous binding sites near genes
that respond differentially to transformation in TRS-HGPS cells
compared to TRS-WT cells (Figure 1G; Table S3), suggesting
regulation of these genes by BRD4. In addition, comparative
analysis of ChIP-seq BRD4 binding sites in TRS-HGPS cells
with misregulated genes in TRS-HGPS-shBRD4 cells showed
a significant overlap between BRD4 binding sites and compo-
nents of the reactivated oncogenic pathways (Table S4). BRD4binding sites were found near multiple genes associated with
RAS signatures (IL8, CXCL1, PLAU, TFPI2), EGFR and VEGF
oncogenic signatures (CXCL2, IL6, CXCL6, SOD2) and transfor-
mation-sensitive genes (COL1A2, COL5A2, COL8A1, CDH11;
Table S4).
BRD4 Protects from Dedifferentiation
during Transformation
A prominent class of gene expression profiles identified in
the GSEA analysis was stem cell gene signatures, which were
enriched in the tumorigenic TRS-HGPS-shBRD4 and TRS-WT
cells, but not in transformation-resistant TRS-HGPS cells (Fig-
ures 6B and S5B), suggesting that loss of BRD4 enabled re-
activation of stem cell gene signatures required to overcome
the block in dedifferentiation observed in TRS-HGPS cells. In
line with this interpretation, TRS-HGPS-shBRD4 cells showed
downregulation of fibroblast-related genes that were unaffected
in TRS-HGPS cells, suggesting successful dedifferentiation of
TRS-HGPS cells upon BRD4 silencing (Figure 6C). In agreement,
shRNA knockdown of BRD4 in TRS-HGPS significantly in-
creased the percentage of cells able to withstand anoikis andCell Reports 9, 248–260, October 9, 2014 ª2014 The Authors 255
to grow as spheres in suspension, a hallmark of normal and ma-
lignant stem cells (Pece et al., 2010; Figure 6D). Furthermore,
treatment of TRS-HGPS cells with the BRD4 inhibitor JQ1
(100 nM) reduced cell viability of the total cell population, but
increased the sphere formation ability of the resistant population
(Figures S5D–S5F). These observations, combined with our
finding that TRS-HGPS cells retain fibroblast-like features, sug-
gest a role of BRD4 in protecting cells from dedifferentiation dur-
ing transformation.
BRD4 Protection in Human Cancer
To explore a possible more general protective role of BRD4
in human cancer, we knocked down BRD4 in wild-type skin
fibroblasts and assessed transformation efficiency. The clono-
genic ability of wild-type cells was increased 2-fold compared
to controls, suggesting a role for BRD4 in tumor protection in
non-HGPS cells (Figure S6B). Consistent with this notion, anal-
ysis using COSMIC identified 111 reported mutations in BRD4
in a collection of 9,624 cancer samples, with 72% of mutations
representing missense mutations likely leading to heterozygous
loss of function. This mutation rate is comparable to that of well-
established tumor suppressors including BLM, BRCA1, CDH11,
and ETV6. To more directly probe the role of BRD4 in human
cancer, we analyzed the expression of BRD4-sensitive genes
identified in HGPS cells in samples from several types of cancer
including acute myeloid leukemia (AML; Metzeler dataset; Metz-
eler et al., 2008; 163 samples), diffuse large B cell lymphoma
(DCBCL; Hummel data set; Hummel et al., 2006; 166 samples),
in which BRD4 has previously been reported to act as a tumor
promoting factor; breast cancer, where BRD4 has antimetastatic
roles (van ’t Veer data set [van ’t Veer et al., 2002], 295 samples;
Hatzis data set [Hatzis et al., 2011]; 508 samples, HER2-negative
only), and lung adenocarcinoma (Kohno data set [Okayama
et al., 2012]; 246 samples), in which variable effects of BRD4 in-
hibition have been reported (Lockwood et al., 2012). We defined
a BRD4 loss-of-function signature (BRD4-KD), consisting of
genes that are significantly upregulated in TRS-HGPS-shBRD4
cells compared to TRS-HGPS cells (Table S3; see Experimental
Procedures), and measured its expression in patients using
GSEA. In all cancers, patients clustered based on the similarity
of their expression profileswith theBRD4-KD signature (Figure 7;
Table S5). Importantly, the BRD4-KD signature was predictive
of patient survival in a cancer-dependent manner. In line with
a tumor-protective role of BRD4, patients with breast cancer ex-
pressing BRD4-sensitive genes similarly to tumor-resistant TRS-
HGPS cells had a significantly better outcome, both in a general
clinical set of breast cancers (p = 0.006) and in a set of HER2-
negative cancers (p = 0.003), whereas patients with patterns
similar to tumorigenic TRS-HGPS-shBRD4 cells had shorter sur-
vival and were enriched in estrogen-resistant/progesterone-
resistant negative cases (p < 0.000001) and radiation-resistant
cases (p = 0.0001; Figures 7 and S6A). Similarly, lung cancer pa-
tients with TRS-HGPS-like profiles had a longer survival (p =
0.004), showed a lower rate of relapse (p = 0.048), had a longer
relapse-free time (p = 0.0077), and lower stage tumors (p = 0.022)
than patients with a TRS-HGPS- shBRD4-like signature (Figures
7and S6A). Furthermore, in both breast and lung cancer data
sets, the BRD4-KD signature positively correlated with prolifera-256 Cell Reports 9, 248–260, October 9, 2014 ª2014 The Authorstion gene signatures (Table S7). The tumor-protective effect of
BRD4 in these cancer types was experimentally confirmed in
colony formation assays, which demonstrated an 7-fold and
2-fold increase, respectively, in the clonogenic capacity of
T47D breast cancer and H358 lung adenocarcinoma cells
upon knockdown of BRD4 using two different shRNAs
(Figure S6B), further supporting a tumor-protective function of
BRD4. In striking contrast, in lymphoma, where BRD4 has
tumor-promoting activity, patients characterized by a TRS-
HGPS-shBRD4-like profile had a better outcome compared
with the HGPS-like profile (p = 0.03; Figure 7) and the BRD4-
KD signature negatively correlated with proliferation gene signa-
tures (Table S7). In AML, BRD4-sensitive genes identified in
HGPS cells had no prognostic value (p = 0.44; Figure 7), suggest-
ing differential gene target specificity for BRD4 in this disease. In
agreement, genes controlled by BRD4 in AML, including c-MYC,
a major mediator of the BRD4 protumorigenic effect, are insen-
sitive to BRD4 knockdown in TRS-HGPS fibroblasts (Figure S7).
Together with our finding that loss of BRD4 in wild-type cells en-
hances experimental transformation (Figure S6B), these results
demonstrate a protective effect of BRD4 in some human cancer
types. The differential behavior of BRD4 target genes in breast
and lung cancer compared to the hematopoietic cancers and
their different prognostic value suggest that BRD4 functions in
a cancer- and tissue-dependent manner.
DISCUSSION
We demonstrate here the existence of a tumor protective mech-
anism in a rare premature aging disease and provide evidence
for its relevance in human cancer. We show that the presence
of progerin renders HGPS cells refractory to oncogenic chal-
lenges by preventing their reprogramming to acquire tumor-initi-
ating ability. We find that ectopic expression of progerin in
tumorigenic wild-type cells is sufficient to override the effect of
both HRAS pathway activation and p53 and pRB inhibition, indi-
cating that the progerin-dependent protective mechanism can
be reactivated in already transformed cells. In line with our find-
ings, the lamin A precursor, prelamin A, has been reported to
have a tumor-protective function (de la Rosa et al., 2013). We
identify BRD4 as a downstream effector of progerin in mediating
resistance to oncogenic transformation. BRD4 acts indepen-
dently of p53 or pRB given that both proteins are inhibited in
our experimental system, as well as telomeres, because telome-
rase is ectopically expressed, and thus represents a tumor-pro-
tective pathway distinct from cellular senescence, which has
been suggested to limit the proliferative potential of HGPS cells
(Kudlow et al., 2008). Importantly, whereas progerin strongly en-
hances the protective function of BRD4 in patients with HGPS,
BRD4-mediated tumor protection is also active in normal individ-
uals, albeit much less potent, as indicated by the observed
increased transformation efficiency of wild-type cells upon
BRD4 knockdown and the prognostic value of BRD4-sensitive
genes in breast and lung cancer.
Our ChIP-seq findings suggest that BRD4 exerts its protective
function in HGPS cells by regulating distinct target genes
as a consequence of progerin-induced redistribution of its
binding sites throughout the genome. HGPS cells have been
Figure 7. BRD4-KD Gene Signature Predicts Clinical Outcomes
Kaplan-Meier analysis of patients affected by the indicated cancer types, with clustering based on the BRD4-KD signature defined using HGPS cells. Each plot
set corresponds to the data set indicated in the top line. Signature expression and clustering of the samples are illustrated in the heatmap bars, with a red (blue)
color indicating significant positive (negative) association with the signature (black color: no significant association, see Experimental Procedures). Patients
showing TRS-HGPS-like expression profiles (absence of the BRD4-KD signature, green cluster) have a better outcome in breast and lung cancer, in line with a
tumor-protective role of BRD4, whereas patients showing TRS-HGPS-shBRD4-like expression profiles (presence of the BRD4-KD signature, red cluster) have a
better outcome in lymphoma, in line with a tumor-promoting role for BRD4. Clustering of patients in AML based on the BRD4-KD signature has no prognostic
value. Statistical significance (log rank test) is indicated in the graph plots.demonstrated to have altered histone modification landscapes
including loss of H3K9me3 and altered acetylation patterns
(McCord et al., 2013; Pegoraro et al., 2009; Scaffidi and Misteli,
2005; Shumaker et al., 2006). These changes are possibly, in
part, brought about by progerin-dependent changes to chro-
matin remodeling and modification factors. For example the his-
tone deacetylase HDAC1, the NURD chromatin remodeling
complex, and the structural heterochromatin protein HP1 are
downregulated in HGPS cells, altering the global chromatin land-
scape (McCord et al., 2013; Pegoraro et al., 2009; Scaffidi and
Misteli, 2005; Shumaker et al., 2006). In line with these observa-
tions, we find altered acetylation patterns in transformed HGPS
cells. The altered histone modification landscape in HGPS cells
creates a distinct set of binding sites for the transcriptional regu-
lator BRD4, leading to altered gene expression programs.
Consistent with the notion that the protective effect of BRD4
seen in HGPS cells is an exaggerated form of the pathway that
is also active in healthy individuals, low levels of progerin are pre-
sent in healthy individuals (Cao et al., 2007; McClintock et al.,2007; Scaffidi and Misteli, 2006), and we find that numerous
binding sites strongly bound by BRD4 in HGPS cells are also
occupied at lower levels in wild-type cells.
Based on analysis of cancer patient cohorts, we suggest our
observations on tumor-protection in HGPS are of general clin-
ical relevance for various cancers. We show that BRD4 target
genes, which mediate tumor resistance in HGPS, have prog-
nostic value in breast and lung cancer. We demonstrate that
BRD4 loss-of-function gene signatures correlate with poor
outcome, in line with a tumor protective role of the protein.
Our observations are in agreement with previous reports
showing that the BRD4 gain-of function signatures are associ-
ated with reduced risk for metastasis in breast cancer (Crawford
et al., 2008) and that restoration of normal levels of BRD4 in co-
lon cancer cells reduces in vivo tumor growth (Rodriguez et al.,
2012). On the other hand, in agreement with the finding that
BRD4 is critically required for disease maintenance in some
hematological cancers and BRD4 inhibition has a strong anti-
leukemic effect, we show that the BRD4 loss-of-function geneCell Reports 9, 248–260, October 9, 2014 ª2014 The Authors 257
signature identified in HGPS cells correlates with good prog-
nosis in lymphoma.
These considerations suggest that BRD4 has a dual role in can-
cer and can either exert a tumor-promoting or tumor-protective
role depending on the cellular context. Precedents for other fac-
tors showing antithetic functions in different cancer types exist
(Dawson and Kouzarides, 2012; Ikushima and Miyazono, 2010;
Ntziachristos et al., 2014). The Notch signaling pathway exerts
an oncogenic function in prostate, colon, and mammary tissue,
whereas it has a tumor-suppressive role in several leukemias
(AML, B-ALL, chronic myelomonocytic leukemia) and lung carci-
nomas (small-cell and squamous cell carcinoma; Ntziachristos
et al., 2014). Similarly, transforming growth factor b acts as a clas-
sical tumor-suppressing factor for most epithelial cells, but pro-
motes proliferation of certain mesenchymal and cancer cells,
and in late stage cancers, it favors metastasis (Ikushima and
Miyazono, 2010). A chromatin-related bifunctional cancer modu-
lator is the polycomb protein EZH2, a histone methyltransferase.
EZH2 is overexpressed in various cancers and high levels of the
protein correlate with poor prognosis in prostate and breast can-
cer, whereas recurrent loss-of-function mutations in EZH2 gene
have been described in the myeloid malignancies and T-ALL
(Dawson and Kouzarides, 2012). The mechanistic basis of the
dual roles of these factors is largely uncharacterized. A possible
explanation for the dual role of BRD4 is that cell-type-specific
chromatin landscapes may dictate their target genes. Histone
acetylation profiles have been shown to stratify cancer cell lines
according to cancer types, with breast and lung cancer cell lines
clustering at the opposite side of the spectrum compared to
leukemic cell lines (Leroy et al., 2013). In agreement, inhibition
of BRD4 alters select sets of genes in a tissue-specific manner
(Dawson et al., 2011; Love´n et al., 2013; Nicodeme et al.,
2010). Gene-specific targeting may also be determined by
different binding partners or by BRD4 phosphorylation status
(Shi et al., 2014; Wu et al., 2013). Moreover, the existence of
multiple BRD4 isoforms generated by alternative splicing may
contribute to the tissue-specific mode of action of the protein (Al-
sarraj et al., 2011; Floyd et al., 2013).
Our findings indicate that human cells have the potential to
counteract oncogenic stimuli through activation of a BRD4-
dependent protective transcriptional program. This pathway is
enhanced in HGPS cells due to the presence of progerin,
but is also active in healthy individuals. The observation of a
tumor-protective role of BRD4 in lung and breast cancer com-
plements earlier observations, which demonstrate a tumor-pro-
moting function of BRD4 in leukemias and lymphoma. Taken
together, these results point to a highly context-dependent
and tissue-specific function of BRD4. Given the intense interest
in using interference with BRD4 function as a therapeutic
approach, BRD4-targeted therapeutic strategies may need to
be cautiously evaluated depending on the cancer type to mini-
mize potentially deleterious effects of these strategies in normal
tissues.EXPERIMENTAL PROCEDURES
The following experimental procedures are described in the Supplemental
Experimental Procedures: cell lines and plasmids, microarrays and gene258 Cell Reports 9, 248–260, October 9, 2014 ª2014 The Authorsexpression analysis, ChIP-sequencing and ChIP- qPCR, quantitative immuno-
fluorescence, western blot and FRAP analysis, and metaanalysis of published
cancer data sets.
Soft-Agar and Nonadherent Sphere Formation Assays
Assays were carried out as previously described (Hahn et al., 1999; Scaffidi
and Misteli, 2011). Briefly, for soft-agar assays cells were plated in six-well
plates (5,000 per well) in 0.35% SeaPlaque Agar (Lonza) in minimum essential
media. For sphere formation, cells were plated in Knockout Dulbecco’s modi-
fied Eagle’s medium (Invitrogen) supplemented with Knockout Serum
Replacement (Invitrogen) in uncoated Petri dishes at clonogenic density
(1,000 cells/ml). Plates were scanned after incubation with MTT (Sigma) at
concentrations of 10 mg/well for soft agar assays and 100 mg/Petri dish for
sphere assays. Colonies and spheres were quantified by using ImageJ soft-
ware. JQ1 (kindly provided by J. Bradner) was dissolved in DMSO and tested
at a final concentration of 100 nM in the sphere formation assay. Media and
fresh drug were replaced every 48 hr for 8 days.
Transplantation Assays
Six-week-old male immunodeficient BALB/cAnNCr-nu/nu mice (from the
Animal Production Program, NCI-Frederick) and NOD/SCID/interleukin 2
receptor gnull mice (NSG, from the Jackson Laboratory) were maintained in
pathogen-free conditions. For generation of tumors, cells (0.5–2.5 3 106 per
injection in 50–100 ml of PBS) were injected intradermally into the flanks of
mice. NSG mice were locally shaved with a depilatory cream 1 day before in-
jection. Tumor growth was assessed twice a week, using a digital caliper, for
up to 10 weeks after injection. Tumor volume was calculated according to the
formula d2D/2, where d and D are the shortest and the longest diameter,
respectively. All procedures were approved by the NIH Animal Use and Care
Committee.
Genome-wide shRNA Screen
Three independent shRNA screens were performed. For each screen, TRS-
HGPS cells (TRS-HGPS2; 6 3 106) were transduced with lentiviral shRNA
particles contained in the GeneNet Human 50k shRNA Library (System Bio-
sciences, SBI). The shRNA library comprises 200,000 probes that target
50,000 human transcripts. Three days after infection, 10 3 106 infected
cells were frozen and used as control samples (see below), whereas 10 3
106 cells were plated in 0.8% SeaPlaque Agar in MEM medium in 170
15 cm2 plates and incubated for colony formation assay. Colonies grown af-
ter 4 weeks (600) were picked and pooled into groups of 150 colonies
each. Total RNA from each pool of colonies or control cells was extracted
with Trizol reagent (Invitrogen) and processed according to the GeneNet
manual to amplify and biotin-label the shRNAs. Labeled RNA was hybrid-
ized onto Human Genome U133 plus 2.0 Affymetrix microarrays. Signal
intensities were retrieved from microarray CEL files according to SBI in-
structions. Independent control samples (whole population of transduced
cells, n = 2) were processed in each screen. Ninety-five percent of shRNAs
comprising the library were detected in control cell samples, indicating
good representation of the library complexity. For each shRNA sequence,
fold change was calculated by dividing intensity value of colony samples
over control samples (mean value of 2 samples) for each of the screens.
We selected shRNAs showing R2-fold enrichment in each independent
screen and considered as positive hits the gene targets of the selected
shRNAs. For validation, individual shRNA were expressed in TRS-HGPS
cells.
Statistical Analysis
Results are presented as mean ± SEM, unless otherwise stated, and derived
from a minimum of three independent experiments. Statistical tests were
performed using GraphPad Prism software package (version 5.0). In general,
we used Student’s t test for comparisons between two experimental groups,
one-way ANOVA followed by Dunnett’s test or Bonferroni multiple t test for
comparisons of more than two groups, and two-way ANOVA to compare
difference between groups at multiple time points. Additional statistical tests
are described in the figure legends. p % 0.05 was considered statistically
significant.
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